50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   271.87 (-2.88%)
AAPL   142.48 (-4.91%)
MSFT   237.50 (-1.48%)
META   136.41 (-3.67%)
GOOGL   97.42 (-2.63%)
AMZN   114.80 (-2.72%)
TSLA   268.21 (-6.81%)
NVDA   122.20 (-4.05%)
NIO   15.58 (-10.10%)
BABA   79.06 (-2.38%)
AMD   64.14 (-6.17%)
T   15.53 (-1.90%)
MU   50.01 (-1.94%)
CGC   2.78 (-8.55%)
F   11.47 (-5.83%)
GE   62.73 (-2.68%)
DIS   97.45 (-1.96%)
AMC   7.10 (-7.43%)
PYPL   88.70 (-2.66%)
PFE   44.16 (-0.61%)
NFLX   239.71 (-2.24%)
QQQ   271.87 (-2.88%)
AAPL   142.48 (-4.91%)
MSFT   237.50 (-1.48%)
META   136.41 (-3.67%)
GOOGL   97.42 (-2.63%)
AMZN   114.80 (-2.72%)
TSLA   268.21 (-6.81%)
NVDA   122.20 (-4.05%)
NIO   15.58 (-10.10%)
BABA   79.06 (-2.38%)
AMD   64.14 (-6.17%)
T   15.53 (-1.90%)
MU   50.01 (-1.94%)
CGC   2.78 (-8.55%)
F   11.47 (-5.83%)
GE   62.73 (-2.68%)
DIS   97.45 (-1.96%)
AMC   7.10 (-7.43%)
PYPL   88.70 (-2.66%)
PFE   44.16 (-0.61%)
NFLX   239.71 (-2.24%)
QQQ   271.87 (-2.88%)
AAPL   142.48 (-4.91%)
MSFT   237.50 (-1.48%)
META   136.41 (-3.67%)
GOOGL   97.42 (-2.63%)
AMZN   114.80 (-2.72%)
TSLA   268.21 (-6.81%)
NVDA   122.20 (-4.05%)
NIO   15.58 (-10.10%)
BABA   79.06 (-2.38%)
AMD   64.14 (-6.17%)
T   15.53 (-1.90%)
MU   50.01 (-1.94%)
CGC   2.78 (-8.55%)
F   11.47 (-5.83%)
GE   62.73 (-2.68%)
DIS   97.45 (-1.96%)
AMC   7.10 (-7.43%)
PYPL   88.70 (-2.66%)
PFE   44.16 (-0.61%)
NFLX   239.71 (-2.24%)
QQQ   271.87 (-2.88%)
AAPL   142.48 (-4.91%)
MSFT   237.50 (-1.48%)
META   136.41 (-3.67%)
GOOGL   97.42 (-2.63%)
AMZN   114.80 (-2.72%)
TSLA   268.21 (-6.81%)
NVDA   122.20 (-4.05%)
NIO   15.58 (-10.10%)
BABA   79.06 (-2.38%)
AMD   64.14 (-6.17%)
T   15.53 (-1.90%)
MU   50.01 (-1.94%)
CGC   2.78 (-8.55%)
F   11.47 (-5.83%)
GE   62.73 (-2.68%)
DIS   97.45 (-1.96%)
AMC   7.10 (-7.43%)
PYPL   88.70 (-2.66%)
PFE   44.16 (-0.61%)
NFLX   239.71 (-2.24%)
NASDAQ:IVA

Inventiva - IVA News Today

$3.83
+0.09 (+2.41%)
(As of 09/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.81
$3.98
50-Day Range
$3.69
$5.42
52-Week Range
$3.60
$15.78
Volume
2,052 shs
Average Volume
14,075 shs
Market Capitalization
$156.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00
Get Inventiva News Delivered to You Automatically

Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter.



IVA Media Mentions By Week

IVA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IVA
News Sentiment

0.51

0.79

Average
Medical
News Sentiment

IVA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IVA Articles
This Week

6

1

IVA Articles
Average Week

SourceHeadline
finance.yahoo.com logoInventiva's NASH Pact In China Represents 'Financially Prudent Pathway,' Says This Analyst
finance.yahoo.com - September 26 at 5:24 PM
MarketBeat logoInventiva (NASDAQ:IVA) Price Target Cut to $36.00 by Analysts at HC Wainwright
americanbankingnews.com - September 26 at 3:38 AM
marketwatch.com logoInventiva ADRs Rise 22% After Licensing Deal With Chia Tai-Tianqing Pharma
marketwatch.com - September 22 at 11:16 AM
finanznachrichten.de logoINVENTIVA: Inventiva reports its 2022 first-half financial results and provides a corporate update
finanznachrichten.de - September 22 at 4:19 AM
finance.yahoo.com logoInventiva reports its 2022 first-half financial results and provides a corporate update
finance.yahoo.com - September 22 at 4:19 AM
finanznachrichten.de logoINVENTIVA: Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China
finanznachrichten.de - September 21 at 6:18 PM
finance.yahoo.com logoInventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China
finance.yahoo.com - September 21 at 6:18 PM
MarketBeat logoInventiva (IVA) Set to Announce Earnings on Wednesday
americanbankingnews.com - September 20 at 1:42 AM
finance.yahoo.com logoHere's Why Inventiva S.A. Sponsored ADR (IVA) is Poised for a Turnaround After Losing 18.4% in 4 Weeks
finance.yahoo.com - September 8 at 11:44 AM
finance.yahoo.com logoInventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results
finance.yahoo.com - September 7 at 6:06 PM
reuters.com logoIVAA.PA - Inventiva SA | Stock Price & Latest News | Reuters
reuters.com - August 22 at 9:13 PM
finanznachrichten.de logoINVENTIVA: Inventiva Reports 2022 First-Half Financial Information¹
finanznachrichten.de - July 28 at 4:25 PM
finance.yahoo.com logoInventiva Reports 2022 First-Half Financial Information¹
finance.yahoo.com - July 28 at 4:25 PM
finance.yahoo.com logoInventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D
finance.yahoo.com - July 7 at 6:55 PM
finanznachrichten.de logoINVENTIVA: Update on Inventiva's cash position and on the finance documentation with the European Investment Bank
finanznachrichten.de - July 4 at 2:42 PM
finance.yahoo.com logoUpdate on Inventiva's cash position and on the finance documentation with the European Investment Bank
finance.yahoo.com - July 4 at 2:42 PM
finanznachrichten.de logoINVENTIVA: Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress 2022
finanznachrichten.de - June 16 at 4:39 PM
finance.yahoo.com logoInventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022
finance.yahoo.com - June 16 at 4:39 PM
finance.yahoo.com logoHere's Why Inventiva S.A. Sponsored ADR (IVA) Could be Great Choice for a Bottom Fisher
finance.yahoo.com - June 15 at 1:17 PM
finance.yahoo.com logoInventiva announces three scientific presentations at the EASL International Liver Congress™ 2022
finance.yahoo.com - June 9 at 6:41 PM
finanznachrichten.de logoINVENTIVA: Inventiva joins the Euronext Tech Leaders segment
finanznachrichten.de - June 7 at 5:33 PM
finance.yahoo.com logoInventiva joins the Euronext Tech Leaders segment
finance.yahoo.com - June 7 at 5:33 PM
finance.yahoo.com logoInventiva announces the presentation of a scientific abstract at the 82nd Scientific Sessions of the American Diabetes Association
finance.yahoo.com - June 3 at 6:40 PM
finanznachrichten.de logoINVENTIVA: Inventiva announces participation at several investors conferences in May and June 2022
finanznachrichten.de - May 23 at 7:45 PM
finance.yahoo.com logoInventiva announces participation at several investors conferences in May and June 2022
finance.yahoo.com - May 23 at 7:44 PM
finance.yahoo.com logoResults of the votes of the Combined Shareholders’ Meeting of May 19, 2022
finance.yahoo.com - May 20 at 6:41 PM
finance.yahoo.com logoDescription of the Share Repurchase Program Authorised by the Ordinary General Meeting of 19 May 2022
finance.yahoo.com - May 19 at 4:35 PM
finanznachrichten.de logoINVENTIVA: Inventiva reports 2022 First Quarter Financial Information and provides clinical development update
finanznachrichten.de - May 17 at 6:43 AM
seekingalpha.com logoInventiva reports Q1 results
seekingalpha.com - May 17 at 1:43 AM
finance.yahoo.com logoInventiva reports 2022 First Quarter Financial Information and provides clinical development update
finance.yahoo.com - May 16 at 7:40 PM
finance.yahoo.com logoInventiva Raises €50M Debt Financing To Fund Its Lead Program In NASH Patients
finance.yahoo.com - May 16 at 3:43 PM
finanznachrichten.de logoINVENTIVA: Inventiva secures a €50 million credit facility from the European Investment Bank
finanznachrichten.de - May 16 at 3:44 AM
finance.yahoo.com logoInventiva secures a €50 million credit facility from the European Investment Bank
finance.yahoo.com - May 16 at 3:44 AM
finance.yahoo.com logoCombined General Meeting of May 19, 2022 - Availability of the preparatory documents
finance.yahoo.com - April 28 at 2:54 PM
finance.yahoo.com logoStatement of total voting rights and shares forming the company’s share capital as of April 11, 2022
finance.yahoo.com - April 28 at 2:54 PM
finanznachrichten.de logoINVENTIVA: Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver
finanznachrichten.de - April 7 at 4:14 PM
finance.yahoo.com logoInventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver
finance.yahoo.com - April 7 at 4:14 PM
finance.yahoo.com logoHow Much Upside is Left in Inventiva S.A. Sponsored ADR (IVA)? Wall Street Analysts Think 166%
finance.yahoo.com - April 5 at 1:40 PM
msn.com logoLa innovación española pierde el tren de la digitalización, según el índice de solicitudes de patentes europeas
msn.com - April 4 at 10:38 PM
finanznachrichten.de logoINVENTIVA: Inventiva announces filing of its 2021 Universal Registration Document and 2021 Annual Report on Form 20-F
finanznachrichten.de - March 11 at 5:52 PM
finance.yahoo.com logoInventiva announces filing of its 2021 Universal Registration Document and 2021 Annual Report on Form 20-F
finance.yahoo.com - March 11 at 5:52 PM
benzinga.com logoInventiva Reports FY21 Sales €4.194M Vs. €372K YoY
benzinga.com - March 9 at 7:33 PM
finance.yahoo.com logoFDA Gives Green Signal To Inventiva's Mid-Stage Lanifibranor Study In NASH Patients
finance.yahoo.com - March 8 at 10:40 PM
seekingalpha.com logoInventiva gets FDA nod to begin phase 2 trial to treat diabetes/liver disease
seekingalpha.com - March 8 at 7:38 AM
finance.yahoo.com logoInventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA
finance.yahoo.com - March 8 at 7:38 AM
finanznachrichten.de logoINVENTIVA: Inventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and cedirogant in psoriasis
finanznachrichten.de - March 7 at 11:43 PM
finance.yahoo.com logoInventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and cedirogant in psoriasis
finance.yahoo.com - March 7 at 11:43 PM
finanznachrichten.de logoINVENTIVA: Inventiva announces participation at several conferences in March 2022
finanznachrichten.de - March 3 at 6:28 PM
finance.yahoo.com logoInventiva announces participation at several conferences in March 2022
finance.yahoo.com - March 1 at 5:30 PM
finanznachrichten.de logoINVENTIVA: Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results
finanznachrichten.de - February 28 at 6:42 PM
Get Inventiva News Delivered to You Automatically

Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:IVA) was last updated on 9/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.